Compound odontomas rarely erupt into the mouth. The presented case is the 13 th case of erupted compound odontoma reported in the literature. The treatment of choice is surgical removal of the odontoma. In the case of odontomas associated to impacted teeth, the teeth should be preserved in wait of spontaneous eruption, or alternatively fenestration followed by orthodontic traction is indicated. Regular follow-up period is crucial to evaluate the prognosis of these teeth.
If the radicular cyst is inadvertently left behind following tooth extraction, some degree of inflammation may carry on. Residual cysts, although to a lesser extend than radicular cysts, have the potential to expand.
Objectives:The purpose of this clinical study was to identify a clinical and histopathological relationship between verrucous hyperplasia, verrucous keratosis, and verrucous carcinoma.Methods:We evaluated 12 patients who had developed oral verrucous carcinoma in the past 10 years in a follow-up study. In this study, the diagnostic criteria included clinical and histopathological features of the lesions. Each lesion was examined by a single oral pathologist.Results:All the patients were diagnosed with verrucous carcinoma following excisional biopsy. One patient was diagnosed with verrucous hyperplasia and another with verrucous keratosis in their initial histological findings. Mandibular, posterior alveolar crest, and retromolar trigone were the most affected sites (41.6%), followed by the buccal mucosa (16.6%), the palate (16.6%), the floor of the mouth (16.6%), and the lip (8.3%). No patients had evidence of recurrence after treatment.Conclusions:Verrucous hyperplasia, verrucous keratosis, and verrucous carcinoma may not be distinguished clinically or may coexist, resulting in diagnostic difficulties. It should be kept in mind that verrucous hyperplasia may also develop from leukoplakic lesions, and it may transform into verrucous carcinoma or squamous-cell carcinoma, acting as a potential precancerous lesion.
No previous studies in the literature have examined in detail so many cases with ST. The demographic profile of the patients with ST presented herein provides useful additional epidemiological information.
ObjectivesThe purpose of this study was to investigate the short-term effects of occlusal splint therapy and tricyclic antidepressants on the bite force and occlusal contact area of patients presenting with nocturnal bruxism.MethodsA maxillary full-coverage hard acrylic splint was applied to the five patients (Group S). Five patients took a tricyclic antidepressant (Amitriptiline HCl, 10 mg/day) for 3 months (Group A) and a control group (Group C) comprising of 10 dental school students with normal occlusion was also formed. Using a Dental Prescale (Fuji Photo Film Corporation, Tokyo, Japan) and an Occluzer computer (FPD703, Fuji Photo Film Corporation, Tokyo, Japan) the bite force and occlusal contact area were measured. The evaluations were made just before the treatment and at 1 month and 3 months of treatment.ResultsThe bite force and occlusal contact area before treatment in study Groups A and S were found to be higher than those in the Group C. Furthermore, the bite force and occlusal contact area increased during treatment in Group A whilst they decreased in Group S. Bite force and occlusal contact area in Group S were lower at both 1 month and 3 months of treatment than in Group C.ConclusionsIt could be tentatively suggested that occlusal splint therapy may be more effective than tricyclic antidepressant in the treatment of bruxism. Further investigations of this measurement method involving larger study populations and a longer follow-up period are needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.